Arkolith/Insider Trading/CTKB/Form 4

Jiang Wenbin

PRESIDENT AND CEO, DirectorCytek Biosciences, Inc. (CTKB) · full profile →Form 4 · filed Mar 12, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
11
6 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 10, 2026Option exercise(M)16K——5.4M
Mar 10, 2026Tax withholding(F)4K$4.23$16K5.4M
Mar 10, 2026Tax withholding(F)9K$4.23$40K5.4M
Mar 10, 2026Option exercise(M)39K——5.4M
Mar 10, 2026Option exercise(M)29K——5.4M
Mar 10, 2026Tax withholding(F)8K$4.23$33K5.4M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 10, 2026Grant(A)915K—$0915K
Mar 10, 2026Option exercise(M)29K—$0177K
Mar 10, 2026Option exercise(M)39K—$0348K
Mar 10, 2026Grant(A)486K—$0486K
Mar 10, 2026Option exercise(M)16K—$047K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001872873-26-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML